Easterly Investment Partners LLC Has $3.14 Million Position in Sanofi (NASDAQ:SNY)

Easterly Investment Partners LLC lowered its holdings in Sanofi (NASDAQ:SNY) by 0.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 54,410 shares of the company’s stock after selling 333 shares during the quarter. Easterly Investment Partners LLC’s holdings in Sanofi were worth $3,136,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. POM Investment Strategies LLC purchased a new position in Sanofi during the 2nd quarter worth $25,000. Larson Financial Group LLC boosted its holdings in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after acquiring an additional 500 shares during the last quarter. Northwest Investment Counselors LLC purchased a new position in Sanofi during the 3rd quarter worth $29,000. Concord Wealth Partners boosted its holdings in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. Finally, Arrow Financial Corp purchased a new position in Sanofi during the 2nd quarter worth $35,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SNY shares. Argus lifted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

Shares of NASDAQ SNY traded down $0.32 during mid-day trading on Friday, reaching $51.41. 317,023 shares of the company’s stock were exchanged, compared to its average volume of 2,020,614. The firm has a market capitalization of $130.47 billion, a price-to-earnings ratio of 26.20, a price-to-earnings-growth ratio of 1.31 and a beta of 0.61. Sanofi has a 52 week low of $45.13 and a 52 week high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a 50-day moving average price of $55.59 and a two-hundred day moving average price of $52.14.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the previous year, the business posted $2.55 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. Analysts predict that Sanofi will post 4.27 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.